These are both Ph2 trials. I like that Novartis is going after both kinds of mutant melanoma with LEE011. Also to remind you they just started a neuroblastoma trial also with LEE011. 4 trials with 3 of them just ramped up.
When melanoma is diagnosed early, it is generally a curable disease. However, when it spreads to other parts of the body, it is the deadliest and most aggressive form of skin cancer. A person with metastatic melanoma typically has on average a short life expectancy that is measured in months. The American Cancer Society estimates there will be more than 76,000 new cases of melanoma and over 9,000 melanoma deaths in the United States in 2012. BRAF and NRAS mutations occur in 50 to 60 percent and 15 to 20 percent of patients with melanoma, respectively.
Interesting. If you saw my post about LEE011 about a week ago, there was actually a question at the Novartis ANALyst day about LEE011. Good to see them expand the trails of it beyond Breast cancer. Looked at the slides from the Novartis R&D day and did not see anything on AT7519. Sure we will here someting soon on it.